Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity
- The Genotype to Phenotype Japan (G2P-Japan) Consortium
- , Ecuador-COVID19 Consortium
- , The CITIID-NIHR BioResource COVID-19 Collaboration
- Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID)
- University of Cambridge
- University of Miyazaki
- The University of Tokyo
- CSIR - Institute of Genomics and Integrative Biology
- University of Washington
- Medical Research Council
- Kumamoto University
- Kuramochi Clinic Interpark
- Research Organization of Information and Systems, National Institute of Genetics Mishima
- Kyoto University
- University College London
- Cambridge University Hospitals NHS Foundation Trust
- Universidad San Francisco de Quito
- Medical Research Council Mitochondrial Biology Unit
- Hiroshima University
- Tokai University
- Hokkaido University
- National Institute of Infectious Diseases
- Tokyo Metropolitan Institute of Public Health
- Laboratorio INTERLAB
- Universidad Espíritu Santo, Ecuador
- Universidad Internacional del Ecuador
- Centros Médicos Dr. Marco Albuja
- Africa Health Research Institute
- University of Cape Town
- Max Planck Institute of Biochemistry
- Wellcome Trust
- Newcastle University
- Humabs BioMed SA
- Howard Hughes Medical Institute
- Max Planck Institute for Infection Biology
- University of KwaZulu-Natal
- NHS Blood and Transplant
- Japan Science and Technology Agency
Producción científica: Contribución a una revista › Artículo › revisión exhaustiva
859
Citas
(Scopus)